[1]钱南南,魏涛华,杨文明,等.中医治疗肝豆状核变性用药规律数据挖掘研究[J].中国中医药信息杂志,2021,28(10):29-36.[doi:10.19879/j.cnki.1005-5304.202105103]
 QIAN Nannan,WEI Taohua,YANG Wenming,et al.Discussion on Medication Rules of TCM in the Treatment of Hepatolenticular Degeneration Based on Data Mining[J].zhongguo zhongyiyao xinxi zazhi,2021,28(10):29-36.[doi:10.19879/j.cnki.1005-5304.202105103]
点击复制

中医治疗肝豆状核变性用药规律数据挖掘研究

参考文献/References:

[1] CZ?/span>ONKOWSKA A, LITWIN T, DUSEK P, et al. Wilson disease[J]. Nature Reviews Disease Primers,2018,4(1):21.

[2] XIE J, WU Z. Wilson’s disease in China[J]. Neuroscience Bulletin,2017,33(3):323-330.

[3] SANDAHL T D, LAURSEN T L, MUNK D E, et al. The prevalence of Wilson’s disease:an update[J]. Hepatology (Baltimore, Md.),2020, 71(2):722-732.

[4] 孙忠人,杨文明.神经病学[M].2版.北京:人民卫生出版社,2016:170.

[5] WANG Y, XIE C, FU D, et al. Clinical efficacy and safety of Chinese herbal medicine for Wilson’s disease:a systematic review of 9 randomized controlled trials[J]. Complementary Therapies in Medicine,2012,20(3):143-154.

[6] XU M, RONG P, JIN T, et al. Chinese herbal medicine for Wilson’s disease:a systematic review and meta-analysis[J]. Frontiers in Pharmacology,2019,10:277.

[7] 中华医学会神经病学分会帕金森病及运动障碍学组.肝豆状核变性的诊断与治疗指南[J].中华神经科杂志,2008,41(8):566-569.

[8] 国家药典委员会.中华人民共和国药典:一部[M].北京:中国医药科技出版社,2020.

[9] 国家中医药管理局中华本草编委会.中华本草[M].上海:上海科学技术出版社,1999.

[10] 钟赣生.中药学[M].北京:中国中医药出版社,2019.

[11] 程婷,李祥,黄鹏,等.肝豆状核变性-伏邪致病新论[J].辽宁中医药大学学报,2019,21(8):64-67.

[12] 杨文明,陈彪.“肝豆状核变性”病名悖论[J].中国实验方剂学杂志, 2004,10(5):61-63.

[13] 杨任民.肝豆状核变性的治疗[J].中国实用儿科杂志,2000,15(2):79-80.

[14] 杨文明,陈彪,鲍远程,等.肝豆状核变性病中医临床思考[J].中国实验方剂学杂志,2004,10(6):66-69.

[15] 汪美霞,汪长春.杨文明从痰瘀论治肝豆状核变性[J].中医药临床杂志,2017,29(7):983-985.

[16] 徐国存,陈怀珍,张静,等.肝豆汤在肝豆状核变性治疗中提高24h尿排铜量和改善作用的观察[J].中医药临床杂志,2012,24(11):1055- 1057.

[17] 张静,方媛,崔圣伟,等.肝豆汤联合二巯基丙磺酸钠对湿热内蕴型肝豆状核变性患者的影响[J].中国实验方剂学杂志,2017,23(17):190- 194.

[18] DING Y, LIU P, CHEN Z, et al. Emodin attenuates lipopolysaccharide-induced acute liver injury via inhibiting the TLR4 signaling pathway in vitro and in vivo[J]. Frontiers in Pharmacology,2018,9:962.

[19] LI X, CHU S, LIU Y, et al. Neuroprotective effects of anthraquinones from Rhubarb in central nervous system diseases[J]. Evidence-based Complementary and Alternative Medicine:eCAM,2019,2019:3790728.

[20] YANG F, DENG L, LI J, et al. Emodin retarded renal fibrosis through regulating HGF and TGFβ-Smad signaling pathway[J]. Drug Design, Development and Therapy,2020,14:3567-3575.

[21] 杜漠.中药排铜筛选方法的初步研究[D].西安:西北大学,2017.

[22] 沈斌,鲍远程.鲍远程辨证治疗肝风(肝豆状核变性)经验[J].河南中医,2017,37(2):227-229.

[23] 张娟,鲍远程,谢道俊,等.肝豆灵对铜负荷大鼠肝纤维化血清代谢组学的影响[J].中医杂志,2014,55(3):232-237.

[24] 陈永华,杨文明,张波,等.解毒化瘀方肝豆灵片治疗肝豆状核变性的临床疗效观察[J].中华中医药杂志,2019,34(1):390-393.

[25] NAGAPPAN A, KIM J, JUNG D Y, et al. Cryptotanshinone from the Salvia miltiorrhiza Bunge attenuates ethanol-induced liver injury by activation of AMPK/SIRT1 and Nrf2 signaling pathways[J]. International Journal of Molecular Sciences,2019, 21(1):265.

[26] WU C, CHEN W, DING H, et al. Salvianolic acid B exerts anti-liver fibrosis effects via inhibition of MAPK-mediated phospho- Smad2/3?/span> at linker regions in vivo and in vitro[J]. Life Sciences, 2019,239:116881.

[27] XIE H, SU D, ZHANG J, et al. Raw and vinegar processed Curcuma wenyujin regulates hepatic fibrosis via bloking TGF-β/Smad signaling pathways and up-regulation of MMP-2/TIMP-1 ratio[J]. Journal of Ethnopharmacology,2020,246:111768.

[28] 杨文明,方芳,汪美霞,等.肝豆扶木汤治疗Wilson病肝纤维化的临床研究[J].中医药临床杂志,2014,26(11):1111-1113.

[29] 唐露露,刘丹青,李睿,等.肝豆扶木汤对TX小鼠肝纤维化的保护作用及机制研究[J].中国中西医结合杂志,2018,38(12):1461-1466.

[30] 唐露露,杨文明,谢文婷,等.肝豆扶木汤对Wilson病肝纤维化TX小鼠肝组织TβRⅠ、TβRⅡ和Smad4表达的影响[J].中华中医药杂志, 2019,34(9):4043-4047.

[31] 杨文明,唐露露,谢文婷,等.肝豆扶木汤对TX小鼠肝纤维化TGF-β1/ Smad信号通路的影响[J].中西医结合心脑血管病杂志,2018,16(4):404-407.

[32] WEI T, HAO W, TANG L, et al. Comprehensive RNA-Seq analysis of potential therapeutic targets of Gan-Dou-Fu-Mu decoction for treatment of Wilson disease using a toxic milk mouse model[J]. Frontiers in Pharmacology,2021,12:622268.

[33] 韩辉,杨文明,张娟,等.肝豆状核变性的中医证候特征[J].中医药临床杂志,2014,26(1):16-19.

相似文献/References:

[1]刘静,刘岩,张汝恩,等.中医药科学数据建设的初步设想[J].中国中医药信息杂志,2007,14(7):99.
 [J].zhongguo zhongyiyao xinxi zazhi,2007,14(10):99.
[2]郑红刚,花宝金,侯炜.中医学术传承的概述与展望[J].中国中医药信息杂志,2010,17(4):5.
 [J].zhongguo zhongyiyao xinxi zazhi,2010,17(10):5.
[3]王婕琼,刘兰林,李泽庚,等.古代中医药有关疫病的预防措施[J].中国中医药信息杂志,2011,18(1):4.[doi:10.3969/j.issn.1005-5304.2011.01.002]
 [J].zhongguo zhongyiyao xinxi zazhi,2011,18(10):4.[doi:10.3969/j.issn.1005-5304.2011.01.002]
[4]王强,房亚玉.基于中医药创新人才培养的专业网络资源学习中心建设[J].中国中医药信息杂志,2011,18(2):7.[doi:10.3969/j.issn.1005-5304.2011.02.004]
[5]施毅.循证医学在中医药领域中的应用现状与前景[J].中国中医药信息杂志,2010,17(6):1.[doi:10.3969/j.issn.1005-5304.2010.06.001]
 [J].zhongguo zhongyiyao xinxi zazhi,2010,17(10):1.[doi:10.3969/j.issn.1005-5304.2010.06.001]
[6]陈璐,鲁静,陈磊.中医药进社区的现状与发展趋势[J].中国中医药信息杂志,2010,17(10):3.[doi:10.3969/j.issn.1005-5304.2010.10.002]
 [J].zhongguo zhongyiyao xinxi zazhi,2010,17(10):3.[doi:10.3969/j.issn.1005-5304.2010.10.002]
[7]杜艳艳.发挥中医药特色优势培养适应农村需求的医疗卫生人才[J].中国中医药信息杂志,2007,14(2):10.
 [J].zhongguo zhongyiyao xinxi zazhi,2007,14(10):10.
[8]童元元,赵英凯,于静,等.关联规则在中医药领域的应用研究[J].中国中医药信息杂志,2009,16(7):95.
 [J].zhongguo zhongyiyao xinxi zazhi,2009,16(10):95.
[9]李春梅,邓媛,刘国正.我国中医药期刊发展现状及主要科技核心期刊文献计量分析[J].中国中医药信息杂志,2009,16(6):99.
[10]张梅,李平.中医药对肿瘤微转移干预思路的探讨[J].中国中医药信息杂志,2007,14(2):79.
 [J].zhongguo zhongyiyao xinxi zazhi,2007,14(10):79.

备注/Memo

基金项目:国家自然科学基金(81973825);国家中医药脑病循证能力提升及平台建设项目(2019XZZX-NB001);安徽中医药大学新安医学教育部重点实验室开放基金(2020xayx12)

更新日期/Last Update:

2021-09-22